Compare CRMT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRMT | NEUP |
|---|---|---|
| Founded | 1981 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 20.6M |
| IPO Year | 2026 | 2002 |
| Metric | CRMT | NEUP |
|---|---|---|
| Price | $3.05 | $3.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $29.50 | $21.00 |
| AVG Volume (30 Days) | ★ 231.1K | 190.3K |
| Earning Date | 06-11-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,281,502,000.00 | $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $3.19 |
| 52 Week High | $47.93 | $21.31 |
| Indicator | CRMT | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 56.56 |
| Support Level | $1.38 | $3.98 |
| Resistance Level | $3.67 | $4.15 |
| Average True Range (ATR) | 0.28 | 0.19 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 14.25 | 44.26 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.